Realta Investment Advisors Reduces Stock Position in GSK plc (NYSE:GSK)

Realta Investment Advisors trimmed its stake in shares of GSK plc (NYSE:GSKFree Report) by 26.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,690 shares of the pharmaceutical company’s stock after selling 2,098 shares during the period. Realta Investment Advisors’ holdings in GSK were worth $211,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Fairfield Bush & CO. purchased a new stake in GSK during the 1st quarter valued at $80,000. JPMorgan Chase & Co. grew its holdings in shares of GSK by 2.3% in the first quarter. JPMorgan Chase & Co. now owns 241,367 shares of the pharmaceutical company’s stock worth $10,514,000 after acquiring an additional 5,518 shares during the period. Panagora Asset Management Inc. purchased a new stake in GSK during the first quarter valued at $467,000. Blair William & Co. IL lifted its holdings in GSK by 3.0% in the first quarter. Blair William & Co. IL now owns 37,192 shares of the pharmaceutical company’s stock valued at $1,620,000 after acquiring an additional 1,094 shares during the period. Finally, Cetera Investment Advisers boosted its position in GSK by 2.4% in the first quarter. Cetera Investment Advisers now owns 62,991 shares of the pharmaceutical company’s stock worth $2,744,000 after purchasing an additional 1,453 shares during the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Price Performance

Shares of NYSE:GSK opened at $42.42 on Tuesday. The company has a market capitalization of $87.30 billion, a P/E ratio of 14.09, a P/E/G ratio of 1.94 and a beta of 0.64. GSK plc has a 1-year low of $33.33 and a 1-year high of $43.84. The firm’s 50 day simple moving average is $41.75 and its two-hundred day simple moving average is $38.44. The company has a debt-to-equity ratio of 1.19, a current ratio of 0.88 and a quick ratio of 0.62.

GSK (NYSE:GSKGet Free Report) last released its earnings results on Wednesday, January 31st. The pharmaceutical company reported $0.72 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.04). The firm had revenue of $10 billion for the quarter, compared to analysts’ expectations of $9.79 billion. GSK had a net margin of 16.24% and a return on equity of 51.45%. Research analysts expect that GSK plc will post 4.07 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 11th. Investors of record on Friday, February 23rd will be given a dividend of $0.3564 per share. The ex-dividend date is Thursday, February 22nd. This represents a $1.43 annualized dividend and a dividend yield of 3.36%. This is a boost from GSK’s previous quarterly dividend of $0.34. GSK’s dividend payout ratio (DPR) is currently 52.82%.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Jefferies Financial Group raised shares of GSK from a “hold” rating to a “buy” rating in a research report on Wednesday, January 3rd. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a research note on Monday, March 4th. Morgan Stanley began coverage on GSK in a research note on Tuesday, January 23rd. They issued an “equal weight” rating for the company. Finally, Citigroup upgraded GSK from a “neutral” rating to a “buy” rating in a research report on Tuesday, February 13th. One analyst has rated the stock with a sell rating, one has issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Check Out Our Latest Analysis on GSK

About GSK

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

Read More

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKFree Report).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.